Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOS: Adjuvant endocrine therapy with or without chemotherapy after neoadjuvant letrozole in postmenopausal breast cancer
jRCTs041180095Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole in breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Disease-free survival. Started May 2008; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs041180095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180095.